Moderna and Merck announce promising results for the personalized vaccine against melanoma recurrence

Moderna and Merck have announced promising final clinical results for a personalized messenger RNA-based therapeutic vaccine administered after the surgical removal of melanoma. Combined with existing immunotherapy, the therapy reduced the risk of recurrence or death by more than 40% among patients enrolled in advanced clinical trials.

The vaccine is created individually for each patient. After surgery, the tumor tissue is genetically sequenced to identify mutations specific to cancer cells. Based on this information, a personalized injection is produced to train the immune system to recognize and destroy any malignant cells that may remain in the body.

The results represent an important advance in immuno-oncology and support expanding research to other forms of cancer, including lung cancer. The approach differs from standard treatments because it aims to adapt therapy to the genetic profile of each tumor.

Widespread implementation remains difficult, however. Individualized production, genetic sequencing, and the time required to manufacture each dose may generate high costs and logistical challenges for public healthcare systems. Companies and researchers must continue to confirm the therapy’s efficacy and safety before it can be used more broadly.